Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Ulcerative Colitis: full-pipeline trial registry
45 of 123 indexed Ulcerative Colitis trials are currently recruiting.
Corpus placement: #97 of 28,707 conditions by registered trial count.
123 US clinical trials · 45 currently recruiting · #97 of 28,707 conditions by registered trial count
Ulcerative Colitis: 123 US clinical trials tracked, 45 recruiting.
Ulcerative Colitis is the subject of 123 registered US clinical trials on ClinicalTrials.gov, 45 of them currently open to new participants. 32 are in Phase 3-4 (later-stage) and 47 in Phase 1-2 (earlier-stage). The most active sponsor is Eli Lilly and Company, running 9 of these trials.
Enrollment posture brief
Registry condition ulcerative-colitis
OPEN 45 | RECR 37% | LATE 32 | EARLY 47 | RANK #97 | SPON 9
Volume-matched condition peers
Nearest open-share peer: Type 2 Diabetes (37% recruiting · 328 trials)
Ulcerative Colitis lists 45 open slots (37% of 123 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Ulcerative Colitis on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Ulcerative Colitis recruits in line with its size-band peers.
45 of 123 indexed trials (36.6%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Ulcerative Colitis trials is spread across many organizations.
Eli Lilly and Company accounts for 9 of 123 trials (7.3%). 72 distinct sponsors appear on at least one study for this condition label.
-
Typical Ulcerative Colitis enrolment sits around 118 participants.
Median target enrolment is 118 among the 123 trials that report a genuine target (sentinel values excluded). 56 of those (45.5%) plan for fewer than 100 participants.
-
Ulcerative Colitis research is mostly interventional.
103 interventional and 20 observational studies make up this index (83.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
123 total, page 1 of 3
Registry and Biorepository for IBD in Central Texas
University of Texas at Austin
NCT04617184
Immune Regulation in Ulcerative Colitis or Crohn s Disease
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00001184
An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis
Sanofi
NCT07184996
A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis
Sanofi
NCT07185009
A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis
Spyre Therapeutics
NCT07012395
A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab
AbbVie
NCT06880744
Patient Preference for Subcutaneous vs. Intravenous Immune Therapy
Diwakar Davar
NCT07223424
A Study of Vedolizumab in Adults With Ulcerative Colitis or Crohn's Disease in the Community Setting
Takeda
NCT06581328
Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
Eli Lilly and Company
NCT06937086
A Biospecimen Collection Study to Identify the Targets of Disease-Reactive T Cells in Patients With Autoimmune Disease
TScan Therapeutics
NCT06587828
LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis:
Eli Lilly and Company
NCT07186101
Treat-to-Target of Endoscopic Remission in Patients With IBD in Symptomatic Remission
University of California, San Diego
NCT05230173
A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)
Takeda
NCT05442567
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of RO7837195 in Participants With Moderately to Severely Active Ulcerative Colitis (UC)
Genentech
NCT06979336
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis
Takeda
NCT06254950
Study of Efficacy and Adherence to Subcutaneous vs. Intravenous Vedolizumab in Patients With Inflammatory Bowel Disease Using a Novel Remote MONITORing Intervention
Mercy Medical Center
NCT06750731
Seattle Spatial Transcriptomic Research in Inflammatory Bowel Disease Evaluation (STRIDE)
Seattle Children's Hospital
NCT06315179
A Continuation Study of TAK-279 in Adults With Ulcerative Colitis (UC) and Crohn's Disease (CD)
Takeda
NCT06764615
Study of Tilpisertib Fosmecarbil in Participants With Moderately to Severely Active Ulcerative Colitis
Gilead Sciences
NCT06029972
A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)
Eli Lilly and Company
NCT04844606
A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis
Eli Lilly and Company
NCT06598943
BOOM-IBD2 Pivotal Clinical Trial
Boomerang Medical
NCT06571669
Hyperbaric Oxygen Therapy for Ulcerative Colitis (HBOT-UC)
Northwestern University
NCT05987852
Tailored Anti-Inflammatory (A-I) Diet for Americans With Ulcerative Colitis (UC)
University of Miami
NCT06784323
A Study to Learn More About How Risankizumab Works in Young Participants With Ulcerative Colitis
AbbVie
NCT07071519
Pilot and Feasibility Study of 2'-FL as a Dietary Supplement in IBD Patients Receiving Stable Maintenance Anti-TNF Therapy
Children's Hospital Medical Center, Cincinnati
NCT03847467
Mirikizumab Real World Protocol
University of North Carolina, Chapel Hill
NCT06696014
A Study to Investigate the Efficacy and Safety of SAR442970 in Adult Participants With Ulcerative Colitis
Sanofi
NCT06975722
The Influence of a Fasting Mimicking Diet on Ulcerative Colitis
Stanford University
NCT03615690
Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Budesonide Extended-release Tablets in Pediatric Subjects Aged 5 to 17 Years With Active, Mild to Moderate Ulcerative Colitis
Bausch Health Americas
NCT04314375
Impact of Prebiotics in Ulcerative Colitis
University of California, Los Angeles
NCT06495658
A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease
Takeda
NCT06100289
IBD-Sleep: A Pilot Study Looking at Changes in Sleep Timing and IBD Symptoms
University of Michigan
NCT06094608
A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC)
Takeda
NCT06095128
A Study of Mirikizumab (LY3074828) in Pediatric Participants With Moderately to Severely or Active Ulcerative Colitis
Eli Lilly and Company
NCT05784246
High Dose Interval Vitamin D Supplementation in Patients With Inflammatory Bowel Disease Receiving Biologic Therapy
Boston Children's Hospital
NCT04331639
Nicotinamide Riboside in Ulcerative Colitis
University of Pittsburgh
NCT05561738
R-3750 in Patients With Mild to Moderate Ulcerative Colitis
Rise Therapeutics
NCT05666960
A Study to Evaluate Etrasimod Treatment in Adolescents With Ulcerative Colitis
Pfizer
NCT05287126
Fermented Food-Supplemented Diet in Ulcerative Colitis
Stanford University
NCT04401605
Treatment of UC With Novel Therapeutics
Brigham and Women's Hospital
NCT06420375
Study of Novel Therapeutics for Acute Remedy of Colitis
Brigham and Women's Hospital
NCT06420492
A Study of Endoscopic Sleeve Gastroplasty for Obesity in Ulcerative Colitis
Mayo Clinic
NCT05739162
Understanding Ozanimod's MOA Via Mass Cytometry in Ulcerative Colitis
University of California, San Diego
NCT06311123
The Use of Butyrate Therapy in Pediatric Ulcerative Colitis
Children's Hospital Los Angeles
NCT05218850
A 5-year Longitudinal Observational Study of Patients Undergoing Therapy for Inflammatory Bowel Disease
Target PharmaSolutions
NCT03251118
A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease
Janssen Biotech
NCT00606346
A Study to Evaluate the Safety of Ozanimod Exposure During Pregnancy in Women With Ulcerative Colitis and Their Infants
Bristol-Myers Squibb
NCT06126835
Filgotinib in Long-Term Extension Study of Adults With Ulcerative Colitis
Alfasigma S.p.A.
NCT02914535
ABTECT - Maintenance
Abivax S.A.
NCT05535946
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 15 |
| Phase 2 | 32 |
| Phase 3 | 28 |
| Phase 4 | 4 |
Top Sponsors
Named interventions
Most-linked intervention names on Ulcerative Colitis records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Ulcerative Colitis trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Ulcerative Colitis page
123 registered trials, 45 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 45 Ulcerative Colitis trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Eli Lilly and Company sponsors the most Ulcerative Colitis trials on record, review their full trial history before evaluating a specific study. See Eli Lilly and Company's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Ulcerative Colitis condition card totals 123 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.